TABLE 3

Characteristics of isolates with decreased susceptibility to quinolonesa

IsolateGenotypeGroupSTPatient age (yr)Patient sexSpecimen typeMIC (mg/liter)Mutation(s) in QRDR
AMPCTRCTXLVXMFXGNXTFXSFXGyrAParC
SMHi67BLNASND66MSputum0.50.2510.510.50.50.03Ser84LeuAsn138Ser, Ser230Ala
SMHi9High-BLNARIII15669MSputum20.2510.130.250.130.130.03Ser84Leu, Glu142Lys
SMHi18High-BLNARIII12185MPharyngeal mucus80.510.130.250.250.130.03Ser84Leu
SMHi90High-BLNARIV5764FSputum320.2520.130.250.250.130.015Ser84Leu
  • a No amino acid substitutions in the QRDRs of GyrB and ParE were observed. M, male; F, female; AMP, ampicillin; CTR, ceftriaxone; CTX, cefotaxime; LVX, levofloxacin; MFX, moxifloxacin; GNX, garenoxacin; TFX, tosufloxacin; SFX, sitafloxacin; ND, not determined because of the failure of fucK amplification by PCR.